Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$2.26 - $3.27 $150,852 - $218,269
-66,749 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$4.99 - $6.57 $333,077 - $438,540
66,749
66,749 $410,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $484M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Michael & Susan Dell Foundation Portfolio

Follow Michael & Susan Dell Foundation and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Michael & Susan Dell Foundation, based on Form 13F filings with the SEC.

News

Stay updated on Michael & Susan Dell Foundation with notifications on news.